Novartis licenses Abogen’s mRNA‑encoded T‑cell engager ABO2203
Novartis has signed a worldwide licensing and option agreement with China‑based Abogen Biosciences for the mRNA‑encoded CD19×CD3 T‑cell engager ABO2203. The deal provides an upfront cash payment of $575 million to Abogen and includes potential milestone payments of up to $7.2 billion, with some reports citing a total possible value of $7.8 billion. The agreement is subject to customary closing conditions, including regulatory approvals.
Why it matters
The upfront cash reduces Abogen’s financing risk while giving Novartis access to a novel RNA platform, but the large milestone upside depends on future development success. Novartis shares fell 0.63% on the news, indicating a modest market reaction to the front‑loaded payment structure.
Key facts
- 1Novartis will pay $575 million upfront to Abogen. streamlinefeed.co.ke
- 2Potential milestone payments could reach about $7.2 billion if all options and milestones are exercised. streamlinefeed.co.ke
- 3Some reports state the total possible deal value could be up to $7.8 billion. biospace.com
- 4The licensed asset is ABO2203, an mRNA‑encoded CD19×CD3 T‑cell engager for autoimmune diseases. streamlinefeed.co.ke
- 5The agreement grants Novartis exclusive worldwide rights and options on additional Abogen RNA platform programs. pharmtech.com
- 6Novartis shares fell 0.63% after the announcement. grafa.com
Open questions
- The total possible deal value is reported as $7.2 billion in some sources and $7.8 billion in others.
Summary written by AlphAI from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.